medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 5

<< Back Next >>

Med Int Mex 2024; 40 (5)

Predictors of treatment response in patients with lupus nephritis associated with thrombotic microangiopathy

Córdoba GS, Osorio MSI, Martínez JSI, Castañeda PS, Uribe RM, Martínez-Sánchez LM

Language: Spanish
References: 47
Page: 305-314
PDF size: 418.04 Kb.


ABSTRACT

Objective: To gather the biomarkers identified in the current literature capable of predicting the response to treatment of patients with lupus nephritis associated with thrombotic microangiopathy.
Materials and Methods: Retrospective study based on a bibliographic search of articles published in the last five years and registered in the databases PubMed, Science Direct, Clinical Key, Google Scholar, Embase, Lilacs and Scielo with the terms MesH lupus nephritis, thrombotic microangiopathy and systemic lupus erythematosus, as well as the key terms treatment and predictors. Studies with outcomes of interest were selected regardless of study type.
Results: Several biomarkers are currently useful in lupus nephritis; among them proteinuria continues to be the strongest biomarker for predicting long-term renal outcome. Many new molecules have proven to be useful in the diagnosis and prognosis of this disease, such as monocyte chemoattractant protein and gelastin-associated lipocalin, among others. Finally, some biomarkers such as VCAM-1, T-CD8 lymphocyte count and CD11b protein decreased with clinical remission.
Conclusions: Lupus nephritis is a frequent complication of systemic lupus erythematosus that associated with thrombotic microangiopathy worsens the prognosis of clinical outcome of the patient, likewise, several diagnostic methods and biomarkers have been identified that can contribute to early and successful intervention in patients with this disease.


REFERENCES

  1. Massicotte-Azarniouch D, Kotzen E, Todd S, Hu Y, HoganSL, Jain K. Kidney thrombotic microangiopathy in lupusnephritis: Impact on treatment and prognosis. Lupus 2022;31 (10): 1175-185. doi:10.1177/09612033221106301

  2. Strufaldi FL, Menezes Neves PDMM, Dias CB, Yu L, WoronikV, Cavalcante LB, et al. Renal thrombotic microangiopathyassociated to worse renal prognosis in Lupus Nephritis.J Nephrol 2021; 34 (4): 1147-156. doi:10.1007/s40620-020-00938-3

  3. Chen W, Liang S, Zuo K, Yang L, Zeng C, Hu W. Clinicopathologicalfeatures and outcomes of SLE patients with renalinjury characterised by thrombotic microangiopathy. ClinRheumatol 2021; 40 (7): 2735-743. doi:10.1007/s10067-021-05627-5

  4. Li C, Yap DYH, Chan G, Wen Y-B, Li H, Tang C, et al. Clinicaloutcomes and clinico-pathological correlations in lupusnephritis with kidney biopsy showing thrombotic microangiopathy.J Rheumatol 2019; 46 (11): 1478-84. DOI:10.3899/jrheum.180773

  5. Hansen DL, Nilsson AC, Frederiksen H. Thrombotic thrombocytopenicpurpura. Ugeskr Laeger 2021; 183 (42).

  6. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathyand the kidney. Clin J Am Soc Nephrol 2018;13 (2): 300-17. DOI: 10.2215/cjn.00620117

  7. Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV,Barbhaiya M, et al. Increased risk of acute and chronic microvascularrenal lesions associated with antiphospholipidantibodies in patients with systemic lupus erythematosus:A systematic review and meta-analysis. Autoimmun Rev2022; 21 (10):103-58. DOI: 10.1016/j.autrev.2022.103158

  8. Kotzen ES, Roy S, Jain K. Antiphospholipid syndromenephropathy and other thrombotic microangiopathiesamong patients with systemic lupus erythematosus. AdvChronic Kidney Dis 2019; 26 (5): 376-86. DOI: 10.1053/j.ackd.2019.08.012

  9. Velo-García A, Castro SG, Isenberg DA. The diagnosisand management of the haematologic manifestationsof lupus. J Autoimmun 2017; 74: 139-60. DOI:10.1016/j.jaut.2016.07.001

  10. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD,Kremer Hovinga J, et al. Consensus on the standardizationof terminology in thrombotic thrombocytopenic purpuraand related thrombotic microangiopathies. J ThrombHaemost 2017; 15 (2): 312-22. DOI: 10.1111/jth.13571

  11. Park MH, Caselman N, Ulmer S, Weitz IC. Complementmediatedthrombotic microangiopathy associated withlupus nephritis. Blood Adv 2018; 16: 2090-4. DOI: 10.1182/bloodadvances.2018019596

  12. Tseng M-H, Fan W-L, Liu H, Yang C-Y, Ding J-J, Lee H-J, et al.Complement factor I mutation may contribute to developmentof thrombotic microangiopathy in lupus nephritis.Front Med (Lausanne) 2020; 7: 609-21. DOI: 10.3389/fmed.2020.621609

  13. Alkhatib MH, Kant S, Menez S, Lakhani L, Sperati CJ, FineDM, et al. Thrombotic microangiopathy versus classIV lupus nephritis in systemic lupus erythematosus. JNephrol 2021; 34 (6): 1907-13. DOI: 10.1007/s40620-021-01010-4

  14. Kello N, Khoury L EI, Marder G, Furie R, Zapantis E, HorowitzDL. Microangiopatía trombótica secundaria en lupuseritematoso sistémico y síndrome antifosfolípido, papeldel complemento y uso de eculizumab:serie de casos yrevisión de la literatura. Semin Artritis Rheum 2019; 49:74-83. Doi:10.1016/j.semarthrit.2018.11.005

  15. Eberhardt HU, Buhlmann D, Hortschansky P, Chen Q, BöhmS, Kemper MJ, et al. La proteína 2 relacionada con el factorH humano (CFHR2) regula la activación del complemento.PLoS One 2013. doi 10.1371/journal.pone.0 078617

  16. de Holanda MI, Pôrto LC, Wagner T, Christiani LF, PalmaLMPP. Use of eculizumab in a systemic lupus erythemathosuspatient presenting thrombotic microangiopathy andheterozygous deletion in CFHR1-CFHR3. A case report andsystematic review. Clin Rheumatol 2017; 36: 2859-67. doi:10.1007s10067-017-3823-2

  17. Roose E, Schelpe AS, Tellier E, Sinkovits G, Joly BS, DekimpeC, et all. Open ADAMTS13, induced by antibodies, is abiomarker for subclinical immune-mediated thromboticthrombocytopenic purpura. Blood 2020; 136 (3): 353-61.doi: 10.1182/blood.2019004221

  18. Moake JL. Microangiopatías trombóticas. N Engl J Med2002; 347: 589-600. doi: 10.1056/NEJMra020528

  19. Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, Li XM, Li XW,Chan TM. Clinical outcomes and clinico-pathological correlationsin lupus nephritis with kidney biopsy showingthrombotic microangiopathy. J Rheumatol 2019; 46 (11):1478-484. doi: 10.3899/jrheum.180773

  20. Curado Borges M, de Miranda Moura Dos Santos F, WeissTelles R, Melo de Andrade MV, Toulson Davisson CorreiaMI, Lanna CCD. Omega-3 fatty acids, inflammatory statusand biochemical markers of patients with systemic lupuserythematosus: a pilot study. Rev Bras Reumatol Engl Ed2017; 57 (6): 526-34. doi: 10.1016/j.rbre.2016.09.014

  21. Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL,Ville S, et al. Eculizumab discontinuation in children andadults with atypical hemolytic-uremic syndrome: a prospectivemulticenter study. Blood 2021; 137 (18): 2438-449.doi: 10.1182/blood.2020009280

  22. Chen X, Cheng W, Wang G, Qi Y, Xiao J, Wang X, Zhao Z.Clinical characteristics and prognosis of renal thromboticmicroangiopathy in lupus nephritis. Iran J Kidney Dis 2021;15 (3): 169-176.

  23. Pivovarova AI, Thongprayoon C, Hansrivijit P, Kaewput W,Qureshi F, Boonpheng B, et al. Thrombotic microangiopathyamong hospitalized patients with systemic lupus erythematosusin the United States. Diseases 2020; 9 (1): 3. doi:10.3390/diseases9010003

  24. Hasni SA, Gupta S, Davis M, et al. Ensayo de seguridad aleatorizadodoble ciego de fase 1 del inhibidor de la quinasaJanus tofacitinib en el lupus eritematoso sistémico. NatComun 2021; 12: 3391. https://doi-org.consultaremota.upb.edu.co/10.1038/s41467-021-23361

  25. Aringer M, Johnson SR. Classifying and diagnosing systemiclupus erythematosus in the 21st century. Rheumatology(Oxford) 2020; 59 (5): 4-11. doi: 10.1093/rheumatology/keaa379

  26. Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis:new progress in diagnosis and treatment. J Autoimmun2022; 132: 102871. doi: 10.1016/j.jaut.2022.102871

  27. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, MohanC. Lupus nephritis. Nat Rev Dis Primers 2020; 6 (1): 7. doi:10.1038/s41572-019-0141-9

  28. Norby GE, Lerang K, Holdaas H, Gran JT, Strøm EH, DraganovB, et al. Lupusnefritt--diagnostikk og behandling [Lupusnephritis--diagnosis and treatment]. Tidsskr Nor Laegeforen2010; 130 (11): 1140-4. doi: 10.4045/tidsskr.09.0583

  29. Kostopoulou M, Adamichou C, Bertsias G. An update onthe diagnosis and management of lupus nephritis. CurrRheumatol Rep 2020; 22 (7): 30. doi: 10.1007/s11926-020-00906-7

  30. Morell M, Pérez F, Marañón C. Immune-related urine biomarkersfor the diagnosis of lupus nephritis. Int J Mol Sci2021; 22 (13): 7143. doi: 10.3390/ijms22137143

  31. Mejia JM, Gómez IA, Cruz C, Méndez RA, ComunidadRA, Uribe NO, et al. Alternative complement pathwayactivation in thrombotic microangiopathy associated withlupus nephritis. Clin Rheumatol 2021; 40 (6): 2233-42. doi:10.1007/s10067-020-05499-1

  32. Caster DJ, Powell DW. Utilization of Biomarkers in LupusNephritis. Adv Chronic Kidney Dis 2019; 26 (5): 351-59. doi:10.1053/j.ackd.2019.09.001

  33. Biomarkers Definitions Working Group.. Biomarkers andsurrogate endpoints: preferred definitions and conceptualframework. Clin Pharmacol Ther 2001; 69 (3): 89-95. doi:10.1067/mcp.2001.113989

  34. Gasparin AA, Pamplona Bueno de Andrade N, Hax V,Tres GL, Veronese FV, Monticielo OA. Urinary biomarkersfor lupus nephritis: the role of the vascular celladhesion molecule-1. Lupus 2019; 28 (3): 265-72. doi:10.1177/0961203319826695

  35. Palazzo L, Lindblom J, Mohan C, Parodis I. Current insightson biomarkers in lupus nephritis: A systematic review ofthe literature. J Clin Med 2022; 11 (19): 5759. doi: 10.3390/jcm11195759

  36. Singer E, Markó L, Paragas N, Barasch J, Dragun D, MüllerDN, et al. Neutrophil gelatinase-associated lipocalin:pathophysiology and clinical applications. Acta Physiol (Oxf)2013; 207 (4): 663-72. doi: 10.1111/apha.12054

  37. Lv W, Booz GW, Wang Y, Fan F, Roman RJ. Inflammationand renal fibrosis: Recent developments on key signalingmolecules as potential therapeutic targets.Eur J Pharmacol 2018; 820: 65-76. doi: 10.1016/j.ejphar.2017.12.016

  38. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, Mc-Cune WJ, et al. The apoptotic ligands TRAIL, TWEAK, andFas ligand mediate monocyte death induced by autologouslupus T cells. J Immunol 2002; 169 (10): 6020-9. doi:10.4049/jimmunol.169.10.6020

  39. Michaelson JS, Wisniacki N, Burkly LC, Putterman C.Role of TWEAK in lupus nephritis: a bench-to-bedsidereview. J Autoimmun 2012; 39 (3): 130-42. doi: 10.1016/j.jaut.2012.05.003

  40. Aulakh GK, Balachandran Y, Liu L, Singh B. Angiostatin inhibitsactivation and migration of neutrophils. Cell Tissue Res2014; 355 (2): 375-96. doi: 10.1007/s00441-013-1753-0

  41. Mok CC, Soliman S, Ho LY, Mohamed FA, Mohamed FI,Mohan C. Urinary angiostatin, CXCL4 and VCAM-1 asbiomarkers of lupus nephritis. Arthritis Res Ther 2018; 20(1): 6. doi: 10.1186/s13075-017-1498-3

  42. Hanaoka M, Gono T, Kawaguchi Y, Uchida K, Koseki Y,Katsumata Y, et al. Urinary free light chain is a potentialbiomarker for ISN/RPS class III/IV lupus nephritis. Rheumatology(Oxford) 2013; 52 (12): 2149-57. doi: 10.1093/rheumatology/ket108

  43. Ganguly S, Majumder S, Kumar S, Gupta R, Muhammed H,Shobha V, et al. Urinary C3d is elevated in patients withactive Lupus nephritis and a fall in its level after 3 monthspredicts response at 6 months on follow up. Lupus 2020;29 (13): 1800-06. doi: 10.1177/0961203320950019

  44. Iwano M, Dohi K, Hirata E, Kurumatani N, Horii Y, Shiiki H,et al. Urinary levels of IL-6 in patients with active lupusnephritis. Clin Nephrol 1993; 40 (1): 16-21.

  45. Enghard P, Rieder C, Kopetschke K, Klocke JR, Undeutsch R,Biesen R, et al. Urinary CD4 T cells identify SLE patients withproliferative lupus nephritis and can be used to monitortreatment response. Ann Rheum Dis 2014; 73 (1): 277-83.doi: 10.1136/annrheumdis-2012-202784

  46. Gupta R, Yadav A, Aggarwal A. Urinary soluble CD163 isa good biomarker for renal disease activity in lupus nephritis.Clin Rheumatol 2021; 40 (3): 941-8. doi: 10.1007/s10067-020-05343-6

  47. Kitagawa A, Tsuboi N, Yokoe Y, Katsuno T, Ikeuchi H, KajiyamaH, et al. Urinary levels of the leukocyte surface moleculeCD11b associate with glomerular inflammation in lupusnephritis. Kidney Int 2019; 95 (3): 680-92. doi: 10.1016/j.kint.2018.10.025




2020     |     www.medigraphic.com